Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report ) - Analysts at Roth Capital upped their FY2028 earnings per share estimates for shares of Nuvectis Pharma in a research report issued on Tuesday, May 7th. Roth Capital analyst J. Aschoff now forecasts that the company will earn $3.90 per share for the year, up from their prior forecast of $3.59. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.52) per share.
Get Nuvectis Pharma alerts:
Sign Up
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report ) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.01).
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $21.00 target price on shares of Nuvectis Pharma in a research report on Wednesday.
Get Our Latest Report on Nuvectis Pharma
Nuvectis Pharma Trading Down 0.8 % Shares of Nuvectis Pharma stock traded down $0.05 during trading on Thursday, reaching $6.38. The stock had a trading volume of 60,451 shares, compared to its average volume of 99,513. Nuvectis Pharma has a 52 week low of $5.92 and a 52 week high of $18.65. The stock has a fifty day moving average price of $8.17 and a two-hundred day moving average price of $8.21. The company has a market capitalization of $117.21 million, a price-to-earnings ratio of -4.50 and a beta of 0.45.
Institutional Investors Weigh In On Nuvectis Pharma A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Strs Ohio lifted its stake in shares of Nuvectis Pharma by 178.6% in the third quarter. Strs Ohio now owns 3,900 shares of the company's stock worth $50,000 after acquiring an additional 2,500 shares during the period. Blue Zone Wealth Advisors LLC bought a new position in shares of Nuvectis Pharma during the 1st quarter worth approximately $118,000. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Nuvectis Pharma during the 4th quarter worth approximately $160,000. Finally, Baldwin Brothers LLC MA lifted its position in Nuvectis Pharma by 22.0% in the 4th quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company's stock valued at $1,185,000 after acquiring an additional 25,660 shares in the last quarter. 96.77% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Nuvectis Pharma In other news, CEO Ron Bentsur bought 5,000 shares of the stock in a transaction dated Monday, March 18th. The shares were bought at an average price of $10.29 per share, for a total transaction of $51,450.00. Following the completion of the purchase, the chief executive officer now owns 3,242,484 shares in the company, valued at $33,365,160.36. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Insiders own 38.85% of the company's stock.
About Nuvectis Pharma (
Get Free Report )
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Further Reading Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
